AFFiRiS AG has Presented Phase I Data on The Trial for the First Parkinson's Vaccine Candidate

First Clinical Data of Therapeutic Parkinson’s Vaccine is Encouraging

AFFiRiS AG has Presented Phase I Data on a Trial for the First Parkinson’s Vaccine Candidate On the 31st of July 2014, AFFiRiS AG announced as a press conference the results of their phase I clinical trial for a vaccine against Parkinson’s disease. ┬áThe vaccine, PD01A, is a therapy that targets the alpha-synuclein protein, a Parkinson’s target. The Michael J.Fox …